Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Praliciguat in Focal Segmental Glomerulosclerosis (FSGS)
NCT07268638Phase 2Recruiting
- Sponsor
- Akebia Therapeutics
- Start
- Dec 2025
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of praliciguat in focal segmental glomerulosclerosis (FSGS), sponsored by Akebia Therapeutics. Started Dec 2025; status: recruiting.
02
Drugs
praliciguat
03
Conditions
focal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on NCT07268638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07268638.